Relevance of two genes in the multidrug resistance of hepatocellular carcinoma: In vivo and clinical studies

Tumori

Volumn 96, Issue 1, 2010, Pages 90-96

  Sun, Zhengang ^a   Zhao, Zizhuo ^b   Li, Gaopeng ^b,c   Dong, Shengli ^d   Huang, Zhiyong ^c   Ye, Lu ^c   Liang, Huifang ^c   Qu, Junyuan ^e   Ai, Xi ^c   Zhang, Wanguang ^c   Chen, Xiaoping ^c  

^a JINGZHOU CENTRAL HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d SHANXI MEDICAL UNIVERSITY   (China)

^e Shanxi Tumour Hospital   (China)

Author keywords

Athymic mice; Hepatocellular carcinoma; Multi drug resistance; Multi drug resistance protein

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; FLUOROURACIL; MESSENGER RNA; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL STRAIN HEPG2; CHEMOEMBOLIZATION; CHEMOLUMINESCENCE; CHILD; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHEMOEMBOLIZATION, THERAPEUTIC; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 77950815774     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1700/479.5657     Document Type: Article

References (41)

1. Okuda K: Hepatocellular carcinoma. J Hepatol, 32: 225-237, 2000.
2. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, Yi CH: Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA, 299: 1669-1677, 2008.
3. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 37: 429-442, 2003.
4. YeoW,Mok TS, Zee B, Leung TW, Lai PB, LauWY, Koh J,Mo FK,Yu SC, Chan AT,Hui P,Ma B, LamKC,HoWM,WongHT, Tang A, Johnson PJ: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst, 97: 1532-1538, 2005.
5. Li Q,Wang J, Sun Y, Cui YL, Juzi JT, Qian BY, Hao XS: Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. Dig Surg, 23: 235-240, 2006. (Pubitemid 44651423)
6. Doyle LA,YangW, Abruzzo LV, Krogmann T, GaoY, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A, 95: 15665-15670, 1998.
7. Uggla B, Stahl E,Wagsater D, Paul C, KarlssonMG, Sirsjo A, Tidefelt U: BCRP mRNA expression vs. clinical outcome in 40 adult AML patients. Leuk Res, 29: 141-146, 2005.
8. Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, Sorrentino BP: Low levels of ABCG2 expression in adult AML blast samples. Blood, 100: 4594-4601, 2002.
9. Lee JS, Scala S,Matsumoto Y, Dickstein B, Robey R, Zhan Z, Altenberg G, Bates SE: Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression. J Cell Biochem, 65: 513-526, 1997.
10. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB: Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Hum Genet, 77: 142-144, 1987.
11. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47: 381-389, 1986.
12. van der Kolk DM, Vellenga E, Scheffer GL, Muller M, Bates SE, Scheper RJ, de Vries EG: Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood, 99: 3763-3770, 2002.
13. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258: 1650-1654, 1992.
14. Scheffer GL,Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Med, 1: 578-582, 1995.
15. Hanania EG, Fu S, Zu Z, Hegewisch-Becker S, Korbling M, Hester J, Durett A, Andreeff M, Mechetner E, Holzmayer T, et al: Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther, 2: 285-294, 1995.
16. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD: Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun, 326: 181-187, 2005.
17. Li G, Chen X,Wang Q, Xu Z, ZhangW, Ye L: The roles of four multi-drug resistance proteins in hepatocellular carcinoma multidrug resistance. J Huazhong Univ Sci Technolog Med Sci, 27: 173-175, 2007.
18. Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci, 21: 69-75, 2004.
19. Rybarova S, Hodorova I, Hajdukova M, Schmidtova K, Mojzis J, Kajo K, Kviatkovska Z, Plank L, Benicky M, Mirossay A, Biros E, Bobrov N,WagnerovaM, Berc A,Mirossay L: Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma, 53: 128-135, 2006.
20. Kamimoto Y, Gatmaitan Z, Hsu J, Arias IM: The function of Gp170, the multidrug resistance gene product, in rat liver canalicular membrane vesicles. J Biol Chem, 264: 11693-11698, 1989.
21. Miyake K,Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res, 59: 8-13, 1999.
22. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res, 59: 4559-4563, 1999.
23. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E: Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res, 62: 5035-5040, 2002.
24. Schneider E,Horton JK,Yang CH, NakagawaM, Cowan KH: Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res, 54: 152-158, 1994.
25. Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJLM, de Vries EGE, Scheper RJ: Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst, 87: 1230-1237, 1995.
26. Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemse PH, van der Zee AG, Suurmeijer AJ: Drug resistance- associated markers P-glycoprotein, multidrug resistance- associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res, 5: 2798-2805, 1999.
27. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Greco WR, Ross DD, Baer MR: Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function. Leukemia, 18: 1252-1257, 2004.
28. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J: Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol, 70: 949-958, 2005.
29. Zhou XF, Yang X,Wang Q, Coburn RA,MorrisME: Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies. Drug Metab Dispos, 33: 1220-1228, 2005.
30. Walter RB, Pirga JL, Cronk MR, Mayer S, Appelbaum FR, Banker DE: PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood, 106: 3584-3593, 2005.
31. Zhang S, Yang X, Coburn RA, Morris ME: Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein. Biochem Pharmacol, 70: 627-639, 2005.
32. Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC: Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemother Pharmacol, 58: 640-653, 2006.
33. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, Keri G, Nemet K, Sarkadi B: Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res, 65: 1770-1777, 2005.
34. Munoz-Martinez F, Lu P, Cortes-Selva F, Perez-Victoria JM, Jimenez IA, Ravelo AG, Sharom FJ, Gamarro F, Castanys S: Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance. Cancer Res, 64: 7130-7138, 2004.
35. Tahara H, Kusuhara H, Fuse E, Sugiyama Y: P-glycoprotein plays amajor role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. DrugMetab Dispos, 33: 963-968, 2005.
36. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM: Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse bloodbrain barrier. Cancer Res, 64: 3296-3301, 2004.
37. Brugger D, Brischwein K, Liu C, Bader P, Niethammer D, Gekeler V, Beck JF: Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. Anticancer Res, 22: 4229-4232, 2002.
38. Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ: HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracyclinebased therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res, 8: 1107-1116, 2002.
39. Okada Y, Tosaka A, Nimura Y, Kikuchi A, Yoshida S, Suzuki M: Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha. Gene, 272: 141-148, 2001.
40. Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, Zwelling LA: Absence of topoisomerase IIbeta in an amsacrine- resistant human leukemia cell line with mutant topoisomerase II alpha. Cancer Res, 58: 5298-5300, 1998.
41. Zhang K, Wong KP, Chow P: Conjugation of chlorambucil with GSH by GST purified from human colon adenocarcinoma cells and its inhibition by plant polyphenols. Life Sci, 72: 2629-2640, 2003.